[ad_1]
By Davit Kirakosyan
10x Genomics, Inc. (NASDAQ:) shares dropped more than 12% after-hours following the company’s preliminary Q2 results, with revenue expected to be approximately $114.5 million (down 1% year-over-year), missing the Street estimate of $127.7 million.
“Our second quarter results fell short of our expectations,” said Serge Saxonov, Co-founder and CEO of 10x Genomics. “We continue to have strong confidence in our longer-term opportunity, technology leadership and the underlying strength of our markets. We are more excited than ever to deliver on the full potential of single cell and spatial biology.”
Burnt-on grease isn't just an eyesore. It stinks up the kitchen and makes cooking a…
Hey there! Ready to embark on a historical journey with Air India? Whether you're a…
In 2017, altcoins were seen as experimental side projects to Bitcoin. By 2021, they became…
Shopping centers in Las Vegas have a unique opportunity to stand out by offering not…
Levitra, a widely recognized medication for treating erectile dysfunction (ED), has proven to be a…
Have you ever looked down at your carpet and wondered if there’s a budget-friendly way…
![](data:image/svg+xml;charset=utf-8,<svg height="400px" width="600px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
